Лизиноприл в лечении артериальной гипертензии у больных с сопутствующей патологией печени


Минушкина Л.О.

ФГУ УНМЦ УД Президента РФ, Москва
Лизиноприл – один из наиболее известных и хорошо изученных ингибиторов ангиотензин-превращающего фермента (ИАПФ), считающийся препаратом-прототипом. Как и у других представителей данной группы, основной механизм действия лизиноприла основан на блокаде активного цинк-содержащего домена АПФ, что ведет к снижению синтеза ангиотензина II и активности ренин-ангиотензин-альдостероновой системы (РААС) в целом. Этот эффект определяет основные показания к назначению ИАПФ. Они применяются при состояниях, в патогенезе которых может играть роль активация РААС, включая артериальную гипертензию. В статье рассмотрены основные фармакокинетические свойства лизиноприла в сравнении с другими препаратами из группы ИАПФ. Рассмотрена антигипертензивная эффективность лизиноприла в монотерапии и в комбинации с другими лекарственными средствами. Проанализированы имеющиеся данные о возможности использования препарата у больных с хроническими заболеваниями печени.

Литература


1. Laher MS, Mulkerrins E, Hosie J, et al. The effects of age and renal impairment on the pharmacokinetics of co-administered lisinopril and hydrochlorothiazide. J Hum Hypertens 1991;5(Suppl. 2):77–84.


2. Macchiarulo C, Pieri R, Mitolo DC, et al. Management of antihypertensive treatment with Lisinopril: a chronotherapeutic approach. Eur Rev Med Pharmacol Sci 1999;3(6):269–75.


3. Landmark K, Tellnes G, Fagerthun HE, et al. Treatment of hypertension with the ACE inhibitor lisinopril. A multicenter study of patients with mild to moderate hypertension in general practice. Tidsskr Nor Laegeforen. 1991; 111(26):3176–19.


4. Motero Carrasco J. A comparative study of the efficacy of lisinopril versus quinapril in controlling light to moderate arterial hypertension. A follow-up with ABPM Rev Esp Cardiol 1995;48(11):746–53.


5. Rosei EA, Rizzoni D, Comini S, et al. Evaluation of the efficacy and tolerability of nebivolol versus lisinopril in the treatment of essential arterial hypertension: a randomized, multicentre, doubleblind study. Blood Press 2003;1(Suppl.):30–5.


6. Jensen HA. Efficacy and tolerability of lisinopril compared with extended release felodipine in patients with essential hypertension. Danish Cooperative Study Group. Clin Exp Hypertens A. 1992;14(6):1095–110.


7. Os I, Bratland B, Dahlof B, at al. Lisinopril or nifedipine in essential hypertension? A Norwegian multicenter study on efficacy, tolerability and quality of life in 828 patients. J Hypertens 1992;10(2).


8. Anichkov DA, Shostak NA, Schastnaya OV. Comparison of rilmenidine and lisinopril on ambulatory blood pressure and plasma lipid and glucose levels in hypertensive women with metabolic syndrome. Curr Med Res Opin 2005;21(1):113–19.


9. Weir MR, Reisin E, Falkner B. Nocturnal reduction of blood pressure and the antihypertensive response to a diuretic or angiotensin converting enzyme inhibitor in obese hypertensive patients. TROPHY Study Group. Am J Hypertens 1998;11(8 Pt 1):914–20.


10. Soffer B, Zhang Z, Miller K, et al. A doubleblind, placebo-controlled, dose-response study of the effectiveness and safety of lisinopril for children with hypertension. Am J Hypertens 2003;16(10):795–800.


11. Alici G, Aliyev F, Bellur G, et al. Effect of seven different modalities of antihypertensive therapy on pulse pressure in patients with newly diagnosed stage I hypertension. Cardiovasc Ther 2009;27(1):4–9.


12. Diamant M, Vincent HH. Lisinopril versus enalapril: evaluation of trough:peak ratio y ambulatory blood pressure monitoring. J Hum Hypertens 1999;13(6):405–12.


13. McInnes GT, O’Kane KP, Istad H. Comparison of the AT1-receptor blocker, candesartan cilexetil, and the ACE inhibitor, lisinopril, in fixed combination with low dose hydrochlorothiazide in hypertensive patients. J Hum Hypertens 2000;14(4):263–69.


14. Leonetti G. Comparison of metabolic and hemodynamic effects of hydrochlorothiazide in monotherapy and in association with lisinopril. An Italian multicenter study Minerva Cardioangiol 1995;43(9):389–98.


15. Mancia G, Zanchetti A, Agabiti-Rosei E. Ambulatory blood pressure is superior to clinic blood pressure in predicting treatment-induced regression of left ventricular hypertrophy Circulation 1997;95:1464–70.


16. Gerc V, Begovic B, Vehabovic M, et al. Fixed combination lisinopril plus hydro-chlorothiazide in the treatment of essential arterial hypertension: an opened, multi-centre, prospective clinical trial. Bosn J Basic Med Sci 2007;7(4):377–82.


17. Gerc V, Begovic B, Vehabovic M, et al. Effects of fixed combination of lisinopril plus hydrochlorothiazide on regression of left ventricular hypertrophy in patients with essential hypertension: an opened, multi-centre, prospective clinical trial. Bosn J Basic Med Sci 2008;8(3):214–19.


18. Mogensen CE, Neldam S, Tikkanen I, et al. Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and noninsulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study. BMJ 2000;321(7274):1440–44.


19. Andersen NH, Poulsen PL, Knudsen ST, et al. Long-term dual blockade with candesartan and lisinopril in hypertensive patients with diabetes: the CALM II study. Diabetes Care 2005;28(2):273–77.


20. Минушкина Л.О. Применение лизиноприла у больных высокого риска при сахарном диабете и метаболическом синдроме // Врач. 2009. № 9. C. 26–31.


21. Fallo F, Dalla Pozza A, et al. Non-alcoholic fatty liver disease is associated with left ventricular diastolic dysfunction in essential hypertension. Nutr Metab Cardiovasc Dis 2009; 19(9):646–53.


22. Fallo F, Dalla Pozza A, Sonino N, et al. Nonalcoholic fatty liver disease, adiponectin and insulin resistance in dipper and nondipper essential hypertensive patients. J Hypertens 2008;26(11):2191–97.


23. Parrilli G, Manguso F, Orsini L, et al. Essential hypertension and chronic viral hepatitis. Dig Liver Dis 2007;39(5):466–72.


24. Song JC, White CM. Clinical pharmacokinetics and selective pharmacodynamics of new angiotensin converting enzyme inhibitors: an update. Clin Pharmacokinet 2002;41(3):207–24.


25. Hayes PC, Plevris JN, Bouchier IA. Pharmacokinetics of enalapril and lisinopril in subjects with normal and impaired hepatic function. J Hum Hypertens 1989;3(Suppl. 1):153–58.


26. Yayama K, Sugiyama K, Miyagi R, et al. Angiotensin-converting enzyme inhibitor enhances liver regeneration following partial hepatectomy: involvement of bradykinin B2 and angiotensin AT1 receptors. Biol Pharm Bull 2007;30(3):591–94.


27. Ramalho FS, Ramalho LN, Castro-e-Silva O, et al. Effect of angiotensin-converting enzyme inhibitors on liver regeneration in rats. Hepatogastroenterology 2002; 49(47):1347–51.


28. Gokcimen A, Kocak A, Kilbas S, et al. Effect of lisinopril on rat liver tissues in L-NAME induced hypertension model. Mol Cell Biochem 2007;296(1–2):159–64.


29. Neal DA, Brown MJ, Wilkinson IB, et al. Hemodynamic effects of amlodipine, bisoprolol, and lisinopril in hypertensive patients after liver transplantation. Transplantation2004;77(5):748–50.


30. Драпкина О.М., Тутнов Д.А. Особенности лечения артериальной гипертензии у больных с заболеваниями печени // Российские медицинские вести. 2008. № 3 (XIII). С. 43–48.


Похожие статьи


Бионика Медиа